Leadership
Alex Huang
EpiQuell Assets & Operations
Alex was responsible for the development of the EpiQuell technology, the creation of the Company’s patent
portfolio of 80 patients and the extensive clinical trials program, and was also responsible for professional
team at LiveLeaf. Alex who built the EpiQuell technology “Hands on” knows the technology, the product
production and all of the prior work that the professional and clinical trial teams did, for this work was
under his command. Alex who is a decorated engineer, has been involved with many world changing
projects. He was responsible for the first flowcytometry device in addition to working closely with Steve
Jobs as a key design engineer at NeXT computer. Today, Alex is a key member of Quotient team helping
us launch the EpiQuell product into the market, helping us have access to the many clinical trial team(s)
of doctors, that helped build the extensive LiveLeaf technology assets and helping us have a clear
understanding how to manufacture the LiveLeaf / EpiQuell product line.
Anders Dahlstrom, M.D., Ph.D.
Scientific Advisor
an internationally recognized expert in mucosal immunity. He is a pediatric gastroenterologist (MD from the Karolinska Institute, Stockholm; PhD in GI Immunology from Karolinska/UCLA). His PhD thesis was on “Long term Parenteral Nutrition in Children: a nutritional, metabolic and immunological study.” In the early 2000s, Dr. Dahlstrom was a co-investigator in countless studies including a five-year study conducted at ICDDRB on “Passive Immunization as Therapy for Gastrointestinal Infections in Children.” From 1996-2005, he was a clinical and research associate professor and since an adjunct professor at Stanford specializing in Autism and chronic pediatric GI diseases.
Dr. Charles Darkoh, Ph.D.
Scientific Advisor
The latest research collaborator with LiveLeaf is a leading expert in the
science of C. Diff treatment and prevention. His NIH funded laboratory is entirely dedicated to research on non-antibiotic means of controlling this pathogen. Dr. Darkoh is a PhD in Molecular Pathology, Microbiology and Molecular Genetics and a tenured associate professor in the Department of Epidemiology, Human Genetics and Environmental Sciences at the Center for Infectious Diseases, University of Texas, School of Public Health. He has 18 peer-reviewed publications, 4 book chapters and was recently awarded a five-year grant by the National Institutes of Health (NIH) to develop a non-antibiotic treatment for Clostridium difficile infections.